A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Durvalumab (Primary) ; MEDI 0457 (Primary)
- Indications Head and neck cancer; Human papillomavirus infections; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 11 Jun 2018 Planned End Date changed from 2 Mar 2020 to 10 Aug 2020.
- 11 Jun 2018 Planned primary completion date changed from 2 Mar 2020 to 10 Aug 2020.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology